COPD Assessment Test (CAT) / Chronic Airways Assessment Test (CAAT)

The COPD Assessment Test (CAT) is a questionnaire for people with Chronic Obstructive Pulmonary Disease (COPD), designed to assess its impact on a person's life. Subsequently it has been used in ILD and bronchiectasis.

The Chronic Airways Assessment Test (CAAT) is a very small validated modification of the CAT to permit its application to asthma as well as COPD.

Please see below for access to the CAT and CAAT.

COPD Assessment Test (CAT) >
Chronic Airways Assessment Test (CAAT) >

Using the CAT or CAAT

The CAT/CAAT digital implementation guide provides additional information for using the questionnaire on a computer or mobile device.

Additional information regarding the CAT/CAAT is available in the CAT User Guide.

If you are a researcher interested in using CAT in a clinical trial and need additional translations, please go to the Mapi Research Trust website to receive all of the required translations.

For additional information on available translations of the CAAT, please email CATmailbox@copdfoundation.org

The CAT Governing Board

  • Professor Michael Polkey, Independent CAT Governance Board Chair
    NIHR Respiratory Biomedical Research Unit at the Royal Brompton and Harefield Foundation NHS Trust and Imperial College
  • Professor Paul Jones, Foundation Chair
    St George's University of London, UK
  • Professor Claus Vogelmeier, GOLD Scientific Committee Chair
    Professor of Medicine and Chair
    Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany
    Member of the German Center for Lung Research (DZL)
  • Professor Mark Dransfield, COPD Foundation Working Group Chair
    Division of Pulmonary, Allergy and Critical Care Medicine
    University of Alabama at Birmingham
  • Professor Toru Oga, Academic Research user
    Department of Respiratory Medicine, Kawasaki Medical School
    577 Matsushima, Kurashiki, Okayama 701-0192, Japan
  • Professor Stephen Rennard, Research User
    University of Nebraska Medical Center
    985910, Omaha, NE, USA 68198-5910
  • Dr Hana Muellerova, AZ Representative and Scientific Advisor
    AstraZeneca, Cambridge, UK
  • Dr. Rafael Alfonso, GSK Representative and Scientific Advisor
    Value Evidence Lead , GSK

For more information, please contact CATmailbox@copdfoundation.org.

The COPD Assessment Test was developed by a multi-disciplinary group of international experts in COPD supported by GSK.

Psychometric validation of CAAT was performed using data from the NOVELTY study funded by AstraZeneca.